醫學系外科學科

Keyphrases

1. 5-fluorouracil (5-FU) 12%
2. 5-year Survival 17%
3. Adverse Radiation Effect 6%
4. After Surgery 7%
5. Arteriovenous Malformation 28%
6. Brain Arteriovenous Malformation (bAVM) 20%
7. Brain Metastases 32%
8. Carcinoembryonic Antigen 17%
9. Carcinoembryonic Antigen Levels 12%
10. Carcinoma 11%
11. Cerebral Arteriovenous Malformation 16%
12. Chemotherapy 16%
13. Clinical Outcomes 9%
14. Clinical Papers 10%
15. Clinical Significance 10%
16. Colon Cancer 15%
17. Colon Cancer Cells 8%
18. Colorectal Cancer 87%
19. Colorectal Cancer Cells 9%
20. Colorectal Cancer Patients 37%
21. Colorectal Carcinoma 6%
22. Completely Resected 9%
23. Confidence Interval 13%
24. Curative Resection 12%
25. Curative Surgery 18%
26. Digital Subtraction Angiography 7%
27. Disease-free Survival 16%
28. Distant Metastasis 10%
29. Dural Arteriovenous Fistula (dAVF) 11%
30. Embolization 6%
31. FOLFOX 6%
32. Gamma Knife Radiosurgery 43%
33. Gastrectomy 6%
34. Gastric Adenocarcinoma 9%
35. Gastric Cancer 43%
36. Gastric Cancer Patients 24%
37. Gastric Carcinoma 9%
38. General Hospital 17%
39. Genetic Modification 10%
40. Hazard Ratio 15%
41. High Risk 9%
42. Independent Prognostic Factor 12%
43. International multicenter Study 21%
44. Intracranial Dural Arteriovenous Fistula 6%
45. Leucovorin 8%
46. Liver Metastasis 9%
47. Local Tumor Control 8%
48. Lung Adenocarcinoma 9%
49. Lymph Node Metastasis 18%
50. Lymphovascular Invasion 8%
51. Magnetic Resonance Imaging 14%
52. Meningioma 8%
53. Meta-analysis 6%
54. Metastasis 9%
55. Metastatic Colorectal Cancer (mCRC) 32%
56. Microsatellite Instability-high (MSI-H) 19%
57. Mortality Rate 6%
58. Multi-institutional Study 8%
59. Multivariate Analysis 21%
60. National Cohort Study 10%
61. Non-small Cell Lung Cancer (NSCLC) 14%
62. Obliteration 14%
63. Odds Ratio 7%
64. Overall Survival 39%
65. Overall Survival Rate 7%
66. Overexpression 16%
67. Oxaliplatin 7%
68. Patient Survival 8%
69. Patients with Colorectal Cancer 13%
70. Polymorphism 6%
71. Poor Prognosis 12%
72. Prognostic Factors 24%
73. Prognostic Indicator 6%
74. Prognostic Significance 8%
75. Prognostic Value 10%
76. Progression-free Survival 7%
77. Radiosurgery 30%
78. Repeat Stereotactic Radiosurgery 6%
79. Resection 15%
80. Right-sided Colon Cancer 7%
81. Risk Factors 12%
82. Stereotactic Radiosurgery 100%
83. Stomach 9%
84. Surgical Outcomes 11%
85. Surgical Resection 8%
86. Survival Rate 7%
87. Taipei 18%
88. Taiwan 33%
89. Taiwanese 6%
90. Transanal Total Mesorectal Excision (taTME) 6%
91. Treatment Outcome 7%
92. Tumor 48%
93. Tumor Cells 7%
94. Tumor Control 7%
95. Tumor Recurrence 9%
96. Tumor Size 10%
97. Tumor Volume 10%
98. Univariate Analysis 7%
99. Vestibular Schwannoma 10%
100. Young Patients 6%

Medicine and Dentistry

1. Abdominal Cancer 56%
2. Adenocarcinoma 7%
3. Apoplexy 6%
4. Arteriovenous Malformation 28%
5. Biological Marker 5%
6. Bleeding 26%
7. Brain Metastasis 29%
8. Breast Cancer 12%
9. Cancer 8%
10. Cancer Cell 9%
11. Carcinoembryonic Antigen 16%
12. Carcinogenesis 6%
13. Carcinoma 9%
14. Cavernous Sinus 6%
15. Cerebral Arteriovenous Malformation 19%
16. Chemoradiotherapy 10%
17. Cohort Analysis 20%
18. Colon 5%
19. Colon Carcinoma 22%
20. Colorectal Carcinoma 77%
21. Colorectal Surgery 5%
22. Disease Free Survival 15%
23. Diseases 27%
24. Distant Metastasis 7%
25. Dural Arteriovenous Fistula 13%
26. Embolization 7%
27. Epidermal Growth Factor Receptor 5%
28. Fasciocutaneous Flap 5%
29. Free Tissue Graft 8%
30. Gamma Knife Radiosurgery 21%
31. Gastrectomy 20%
32. Gene Mutation 9%
33. Hazard Ratio 11%
34. In Vitro 6%
35. Intracranial Tumor 5%
36. Laparoscopic Surgery 8%
37. Liver Metastasis 9%
38. Lung Adenocarcinoma 10%
39. Lung Cancer 14%
40. Lymph Node 13%
41. Lymph Node Metastasis 20%
42. Lymphovascular Invasion 7%
43. Magnetic Resonance Imaging 10%
44. Malignant Neoplasm 16%
45. Meningioma 10%
46. Meta-Analysis 5%
47. Metastasectomy 7%
48. Metastatic Carcinoma 25%
49. Metastatic Colorectal Cancer 6%
50. Microsatellite Instability 7%
51. Mortality Rate 6%
52. Multivariate Analysis 15%
53. Neoplasm 89%
54. Non Small Cell Lung Cancer 12%
55. Odds Ratio 5%
56. Overall Survival 43%
57. Pediatrics 6%
58. Pneumonectomy 5%
59. Primary Tumor 6%
60. Prognostic Factor 30%
61. Progression Free Survival 6%
62. Proportional Hazards Model 8%
63. Quality of Life 5%
64. Radiation Necrosis 5%
65. Radiation Response 5%
66. Radiation Therapy 7%
67. Radiosurgery 25%
68. Randomized Controlled Trial 5%
69. Rectum Cancer 20%
70. Recurrent Disease 34%
71. Retroperitoneal Lymph Node Dissection 6%
72. Retrospective Cohort Study 5%
73. Retrospective Study 9%
74. Squamous Cell Carcinoma 5%
75. Stereotactic Radiosurgery 86%
76. Stomach Adenocarcinoma 7%
77. Stomach Carcinoma 7%
78. Surgery 45%
79. Survival Rate 19%
80. Total Mesorectal Excision 6%
81. Tumor Cell 5%
82. Tumor Progression 6%
83. Tumor Recurrence 6%
84. Univariate Analysis 6%
85. Vestibular Schwannoma 7%